Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT01278615 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

NIH

Sponsor class

Stopped Closed Prematurely.

Conditions

Recurrent Adult Diffuse Large Cell Lymphoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selumetinib

Sponsor

National Cancer Institute (NCI)